Drugs for genital or sexual disorders and contraceptives (A61P15)

A   Human necessities(312083)
A61P15                 Drugs for genital or sexual disorders (for disorders of sex hormones a61p0005240000); contraceptives(956)
ethod for treatment of recurrent vulvovaginal candidiasis // 2642666
FIELD: medicine.SUBSTANCE: immunomodulatory therapy is administered by local action on the cervico-vaginal area with a drug containing sodium aminodihydrophthalazinedione, represented by the rectal suppositories Galavit, by introduction into the cervico-vaginal zone in successive doses of 100 mg overnight in three steps: the first preparatory phase of recovery of functional metabolic activity of cervical secret neutrophilic granulocytes by stimulation of their microbicidal activity by daily administration of the said drug with a course of 5 doses, one dose per day; the second stage of normalization of the monocyte-macrophagal system in the cervico-vaginal zone by enhancing phagocytosis using this drug with a course of 5 doses at a single dose with 48 hours pauses between them; the third stage of formation of a stable immune response in the cervico-vaginal zone at the local level by introduction of this drug with a course of 10 doses at a single dose with 72 hours pauses, and administration of a systemic antimycotic, which is itraconazole administered orally at a dose of 200 mg 1 dose daily, is performed at the third stage, starting with the administration of the 15th dose of Galavit.EFFECT: normalization of the local immune status, with preservation of a full-fledged immune response in the long-term period, a stable immunity is provided, with a reduction in the number of relapses and a reduction in the duration of treatment.3 cl, 2 tbl, 2 ex
N-acetyl-l-cysteine for application in extracorporeal fertilization // 2641606
FIELD: pharmacology.SUBSTANCE: invention is a pharmaceutical composition containing N-acetyl-L-cysteine (NAC) alone or together with (2) selenium in the form of selenomethionine and/or (3) melatonin and/or their physiologically acceptable salts and a suitable carrier or an excipient for application in IVF treatment of infertility in a mammal, characterized by a NAC dose of 50-150 mg/kg of body weight administered intravenously or a NAC dose of 30-45 mg/kg of body weight is administered once daily for 1 to 3 days orally, or alternatively, 600 mg of NAC is administered three times a day orally for three consecutive days in a week, followed by four days without drug administration for a total of three months or more before IVF-treatment.EFFECT: higher percentage of live births.1 tbl, 12 cl, 1 dwg
ethod for treatment and prevention of reproductive function violations in cows // 2641051
FIELD: veterinary medicine.SUBSTANCE: preparation of the following composition: glucose - 45.0, calcium chloride - 10.0, potassium chloride - 2.0, sodium chloride - 6.0, magnesium chloride hexahydral - 4.0, bidistilled water up to 1000 ml, pH 6, 8-7.5 - is administered to the abdominal cavity three times for 72 hours at a rate of 1 ml per 1 kg of the animal live weight.EFFECT: method allows to improve the reproductive ability of animals.2 tbl, 2 ex
ethod of treatment of subclinical mastitis of lactating cows // 2640926
FIELD: veterinary medicine.SUBSTANCE: cows are intramammary inserted into the affected udder quarter with the therapeutic agent "Malavit" at a concentration of 15-25%. The specified agent is injected after morning milking in a dose of 20-30 ml once a day within 5-7 days.EFFECT: method provides a new technique for treating latent mastitis of cows by expanding the range of the medicinal agents used.3 ex
Peroral compositions containing ester 17- hydroxyprohesteron, and corresponding methods // 2640912
FIELD: pharmacology.SUBSTANCE: bioavailable peroral dosage forms are proposed, containing 17-hydroxyprohesteron caproate in the form of particles with an average diameter of 50 micron or less, as well as corresponding methods. Said peroral dosage forms can be prepared for pregnancy maintenance and contain a therapeutically effective amount of 17-hydroxyprohesteron caproate and pharmaceutically acceptable carrier. At least 20 wt % of 17-hydroxyprohesteron ester dose escape from said peroral dosage forms during determination using a device for dissolution of 2nd type in accordance with USP in 900 ml of deionised water with 0.5% (wt/vol) of sodium lauryl sulphate at 50 rpm and 37°C in 60 minutes.EFFECT: peroral form with high bioavailability.54 cl, 3 dwg, 54 ex, 14 tbl
ethod for endothelioprotection in adma-similar gestosis model by arginase ii inhibitor // 2639415
FIELD: pharmacology.SUBSTANCE: method involves reproduction of gestosis in laboratory pregnant Wistar rats by daily intraperitoneal administration of the NO-synthase inhibitor L-NAME from day 14 to day 20 of pregnancy at a dose of 25 mg/kg/day. At that, correction of endothelial dysfunction is performed daily by intragastric administration of a selective inhibitor of arginase II-KUD975. Inhibitor administration is performed 30 minutes prior to the administration of L-NAME at a dose of 1 mg/kg of animal body weight.EFFECT: pronounced correction of dysfunction under the conditions of specific mechanisms of the pathological process in pregnant women, with elimination of side effects typical for low- and nonselective arginase inhibitors.1 ex
Preparation for infectious inflammatory diseases treatment and/or prevention // 2639129
FIELD: pharmacology.SUBSTANCE: invention relates to an antiseptic preparation in the form of a gel that contains chlorhexidine gluconate-0.01-0.5 g, methyl-4-hydroxybenzoate-0.01-0.1 g, ethyl 4-hydroxybenzoate-0.01-0.1 g, propyl-4-hydroxybenzoate-0.01-0.1 g, propylene glycol 5-70 g, hydroxyethylcellulose – 1.5-5 g and water - up to 100 g.EFFECT: creation of a new drug that is effective against pathogens that cause sexually transmitted diseases and is not toxic and irritating.3 cl, 8 ex, 2 tbl
eans for post-delivery endometritis prevention in cows // 2638038
FIELD: veterinary medicine.SUBSTANCE: product contains glucose-saline solution, lysine and methionine amino acids, each taken at the rate of 19.0-21.0 g per1 litre, as well as novocaine at the rate of 4.5-5.5 g per 1 litre.EFFECT: increased effectiveness of post-delivery endometritis prevention in cows, cows' liver protection after calving and pathogenetic effects on the cows' uterus.1 ex
ethod for vaginal atrophy treatment in women in postmenopause considering vaginal epithelium and microbiocenosis state // 2636619
FIELD: medicine.SUBSTANCE: bio material is taken using a vaginal or urethral probe by scraping the vagina. The number of genomic equivalents of microorganism and their fraction in the total bacterial mass are determined using the "Femoflor-16" reagent kit by real-time PCR. If the proportion of Lactobacillus spp. is more than 80%, normocenosis, characterized by the dominance of normoflora is diagnosed. If the proportion of Lactobacillus spp. is less than 80%, dysbiosis is diagnosed. At vaginal atrophy against a background of normocoenosis hormonal therapy is appointed. At a vaginal atrophy against a background of dysbiosis hormonal therapy and lactic culture containing preparations are appointed.EFFECT: invention provides development of individual approaches to vaginal atrophy treatment in postmenopausal women, taking into account the state of the vaginal biocenosis.5 tbl, 3 ex

Pharmaceutical compositions and its application in female sexual dysfunction treatment // 2636501
FIELD: pharmacology.SUBSTANCE: invention relates to the female sexual dysfunction treatment. The application of the PDE5 inhibitor and the dihydrotestosterone combination is offered. This combination is for the production of the medicinal agent for female sexual disorder treatment, where the noted PDE5 inhibitor (sildenafil, tadalafil or vardenafil) is used in 1-2 hours before the sexual activity and the dihydrotestosterone is in the form of the sublingual preparative form and is used in 3.5-5.5 hours before the sexual activity.EFFECT: psychological sexual excitement increase.7 cl, 5 dwg
ethod for treatment of chronic endometritis with autoimmune endometrium disorders // 2635518
FIELD: medicine.SUBSTANCE: for treatment of chronic endometritis with autoimmune endometrium disorders, a sterile and warmed to a body temperature of 36.6-37°C 0.02% solution of gepon (2.0 ml) is prescribed intrauterinely once a day for 10 days as pathogenetic treatment of chronic autoimmune endometritis from the 5th day of the menstrual cycle.EFFECT: invention provides relief of the inflammatory process, restoration of endometrium sensitivity to its own hormones and restoration of the endometrium glandulocyte secretory activity.1 ex
Application of tungsten (vi) salts for treatment of female infertility in mammals without diabetes // 2635507
FIELD: medicine.SUBSTANCE: invention can be used to treat female infertility in non-diabetic mammals by administering a therapeutically effective amount of a tungsten (VI) salt with a pharmaceutically or veterinarily suitable cationic group or a solvate thereof.EFFECT: method allows to restore ovulation and increase zygote implantation into the uterine wall.25 cl, 4 tbl
ethod for obtaining of integrated preparation for optimisation of cows reproductive function in case of metabolic disorder // 2635468
FIELD: veterinary medicine.SUBSTANCE: method involves boiling of a solvent where an active ingredient is added, followed by additional solution boiling for at least 15 minutes, bidistilled water is used as the solvent, and magnesium chloride, hexachloride, calcium chloride, sodium chloride and potassium chloride at pH 6.8-7.5 are used as active substances.EFFECT: increased drug effectiveness.2 tbl, 1 ex
ethod for prevention of acute postpartum and chronic hidden inflammatory processes in reproductive organs of breeding pigs // 2635187
FIELD: veterinary medicine.SUBSTANCE: breeding pigs receive probiotic preparation "Giprolam" at a dose of 50 ml per animal intravaginally during the last three days before farrowing and during three days from day 8-10 of lactation, every 24 hours.EFFECT: invention allows simultaneous prevention of inflammatory processes in the reproductive organs of breeding pigs, manifested both as acute postpartum endometritis, metritis-mastitis-agalactia, and latent chronic endometritis.10 tbl, 2 ex
ethod of treatment of chronic prostatite complicated by stones of prostate // 2634685
FIELD: medicine.SUBSTANCE: for the treatment of chronic prostatitis complicated with prostate stones, extracorporeal shock wave therapy (ESWT) with a frequency of 5 Hz, a 5-6th energy level (according to sensations), 2000 pulses per session, 2 times a week, for a course of 8 procedures for four weeks. In addition, phytotherapy is carried out by administering kanefron 2 tablets three times a day for a month.EFFECT: method ensures the disintegration of the formed calculi and their outward excretion, the improvement of diuresis and the transfer of the turbulent flow of urine into laminar flow, prevention of urine inclusions into the excretory ducts of the prostate gland.1 tbl, 1 ex
ethod for local treatment of postpartum endometritis // 2634471
FIELD: medicine.SUBSTANCE: for the local treatment of postpartum endometritis. To do this, complex therapy is carried out, which includes intrauterine injection of ultrasonically cavity medicated solutions. For uterine cavity ultrasonic treatment, a solution containing 1 μg of Betaleukin preparation and 400 ml of 0.9% saline is used. Two procedures are performed every other day at a frequency of ultrasonic oscillations of 25 kHz, the amplitude of ultrasonic waveguide instrument oscillations is 60-120 mcm, drug solution consumption is 100-150 ml/min, exposure is 3-5 min, infusion volume is at least 300 ml.EFFECT: reduced duration of treatment, reduced likelihood of severity, recurrence and chronicization of the inflammatory process and the need for subsequent surgical treatment due to rapid and persistent reduction of the inflammatory process and cytokine imbalance at the local level.2 cl, 1 ex
Application of "oyster mycelium "revitacel" based on pleurotus ostreatus fungus strain vkpm f-819, having effect on male reproductive function // 2634384
FIELD: medicine.SUBSTANCE: application of "Oyster Mycelium Extract "REVITACEL" extract as a drug for increasing the percentage of the level of increased activity of human spermatozoa.EFFECT: increased male reproductive function.2 tbl
ethod for prevention of hidden endometritis in breeding pigs // 2633489
FIELD: veterinary medicine.SUBSTANCE: probiotic preparation "Giprolam" is administered intravaginally to lactating pigs on day 8-10 after farrowing, daily for 3 days with an interval of 24 hours.EFFECT: application of the claimed method contributes to the optimal content of indigenous microbiota in the genital tract, prevents colonization of opportunistic and pathogenic microorganisms and prevents the onset of hidden endometritis.6 tbl, 2 ex
Pharmaceutical composition with prolonged action of gonadotropins for induction of superovulation in female mammals // 2633079
FIELD: pharmacology.SUBSTANCE: invention is a composition comprising follicle-stimulating hormone (FSH) and luteinizing hormone (LH) at FSH/LH ratios (1/0.001-1/1) and a follicle stimulating hormone prolonging agent - a biologically degradable polyethylene glycol (PEG) polymer, characterized by additional content of 0.25-1% solution of novocaine, and PEG with a molecular weight of 6,000 to 70,000 Da is used as a prolongator, with the following proportions of components: FSH/LH (1/0.001-1/1) with an activity of 800-1000 IU in 0.25-1% solution of novocaine from 65 to 90 wt %; PEG with a weight of 6000 to 70,000 D, 10 to 35 wt %.EFFECT: increased number of eggs suitable for fertilization.2 tbl, 3 ex
ethod for optimisation of men cardiotropic therapy and hormone replacement therapy in case of androgenodeficiency with arterial hypertension // 2632449
FIELD: medicine.SUBSTANCE: young men undergo electrocardiography, echocardiography, vessels doppler, Holter-monitoring of arterial pressure, heart and blood vessels, arterial pressure level, psychological state, social aspects of life are examined, followed by the introduction of minimal doses of "Equator" - 10 mg of lisinopril and 5 mg of amlodipine and minimal doses of HRT as transdermal "Androgel" at a dose of 50 mg of testosterone per day for 6 months.EFFECT: method allows to increase the effectiveness of combined therapy in men with androgen deficiency and arterial hypertension due to improved structural, geometric, systolic and diastolic parameters of the left ventricle with improvement of endothelial and erectile function.4 tbl
ethod for bacterial vaginosis treatment or prevention // 2632110
FIELD: medicine.SUBSTANCE: invention relates to methods for bacterial vaginosis treatment or prevention, bacterial vaginosis recurrence prevention, and bacterial vaginosis symptoms alleviation or prevention in a subject. The methods comprise administration of an effective amount of a macromolecule, a polylysine-based dendrimer, polyamidoamine or poly(propyleneimine) of generations 1-5 and one or more sulfonic acid-containing functional groups attached thereto.EFFECT: increased efficiency of treatment.36 cl, 6 tbl, 4 ex
ethod for complex conservative treatment of uterine myoma // 2632105
FIELD: medicine.SUBSTANCE: complex conservative treatment of uterine myoma is carried out in two stages: prehormonal preparation and hormonal drugs are prescribed. At the first stage, 1 month before hormone therapy appointment, on the third day of the menstrual cycle, an immunotherapy course with Pyrogenal is prescribed at a dose of 25 mcg intramuscularly every 48 hours with a sequential increase in the dose by 25 mcg until the body temperature is raised to at least 38°C, but not more than the maximum dose of 150 mcg of Pyrogenal. From the moment of temperature increase, the combined antibacterial, antiprotozoal, antimycotic and antiviral therapy starts in combination with EHF-therapy - daily for 30 minutes per sternum area at the level of the 2nd rib, for 10 days. In the next cycle, hormone therapy is prescribed for 3 months by any of the known drugs.EFFECT: use of the invention allows to increase the efficacy of conservative treatment of uterine myoma, reliably prevent the complications of hormone therapy and the relapse of tumor growth.5 tbl, 2 ex
ethod to increase frequency of embryo implantation in mammal mother uterus, application of effective amount of beta-galactoside-binding lectine or its derivatives, beta-galactosid-binding lectine or derivatives and product // 2631598
FIELD: medicine.SUBSTANCE: method is implemented by introduction of an effective amount of beta-galactoside-binding lectin or its alkylated form into the uterus of a mammal before the preimplantation period. The invention relates to application of an effective amount of beta-galactoside-binding lectin or its alkylated form to increase the frequency of embryo implantation in a mammal uterus by implementing the method, as well as to a product for increasing the frequency of embryo implantation in a healthy mammal uterus comprising an effective amount of beta-galactoside-binding lectin or its alkylated form.EFFECT: product application increases the number of embryonic implants in the uterus.17 cl, 2 tbl

Pharmaceutical composition // 2630617
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition for treatment of cyclooxygenase-2 mediated diseases is described. The said composition includes, (2S)-7-tret-butyl-6-chloro-2- (trifluoromethyl)-2H-chromene-3-carboxylic acid as the active substance and a filler selected from tromethamine or meglumine. The filler is used in an amount of 0.5 wt % to 70 wt %. Two versions of the method for preparation of this composition and its application are also described.EFFECT: increased dissolution rate and oral bioavailability of the said composition, including the free form of the said compound.9 cl, 5 dwg, 16 tbl, 6 ex
Combination of traditional chinese medicine for immune function regulation and method for its production // 2630056
FIELD: pharmacology.SUBSTANCE: composition of traditional Chinese medicine for immunity regulation, which contains the following raw materials in parts by weight: 1-100 parts of Radix Panacis Quinquefolii, 1-100 parts of Ganoderma, 1-60 parts of Cordyceps sinensis fermented powder, 1-60 parts of Flos Rosae Rugosae and 1-60 parts of Rhizoma Anemarrhenae or one or more of their extracts. A composition of traditional Chinese medicine for immunity regulation. containing the following raw materials in parts by weight: (i) 1-100 parts of any of Radix Et Rhizoma Ginseng, Radix Codonopsis, Radix Pseudostellariae or Radix Astragali, or any of Radix Et Rhizoma Ginseng extract, Extract of Radix Codonopsis, extract of Radix Pseudostellariae or extract of Radix Astragali; (ii) 1-100 parts of Gandorema; (iii) 1-60 parts of Cordyceps or Cordyceps extract; (iv) 1-60 parts of Flos Rosae Rugosae and (v) 1-60 parts of Rhizoma Anemarrhenae. Method for obtaining of a composition of traditional Chinese medicine. Use of the composition in the manufacture of a medicament for allergic diseases prevention and treatment. Allergic diseases include allergic rhinitis, allergic asthma, atopic dermatitis and/or urticaria. Composition application in the manufacture of a medicament for viral diseases prevention and treatment. Viral diseases include hepatitis B and/or AIDS. Composition application for manufacture of a medicament that is effective in increasing of the leukocytes number. Composition application for manufacture of a medicament for radiation injury prevention and treatment. Composition application for manufacture of a medicament to reduce toxic and/or side effects resulting from radiation therapy and chemotherapy. Composition application for manufacture of a medicament for male sexual function improvement. Composition application for manufacture of a medicament for human body immunity enhancement. Composition application for production of a dietary food product or a medicament to alleviate physical fatigue.EFFECT: compositions described above are effective for immunity regulation.18 cl, 19 ex, 13 tbl
Preparation for folliculogenesis stimulation and method for its application // 2629871
FIELD: medicine.SUBSTANCE: group of inventions concerns a preparation for folliculogenesis stimulation containing a suspension of chimeric protein with water-insoluble enzymatically inactive chloramphenicol acetyltransferase without 10 C-terminal amino acids, an amino acid spacer and somatostatin-14 with the amino acid sequence AGCFWKTFTSC in refined vegetable oil with addition of pyrogen-free water for injection. The group of inventions also relates to a method for folliculogenesis stimulation, which involves two-fold subcutaneous injection of the drug.EFFECT: folliculogenesis stimulation by a somatostatin-containing drug.6 cl, 1 ex, 14 dwg, 8 tbl

Pharmaceutical compositions comprising oligomeric lactic acid // 2627470
FIELD: pharmacology.SUBSTANCE: invention provides a composition comprising i) an oligomeric lactic acid of formula (I) wherein n is an integer from 2 to 20, 2 to 19, or 2 to 18, and wherein the content of the oligomeric lactic acid which is a trimer, i.e, HL3, which coefficient n is 2, is approx. 10 to approx. 20 wt % of the oligomeric lactic acid total weight. The average molecular weight Mn of the oligomeric lactic acid is approx. 200 to approx. 500, and ii) a mucoadhesive agent. The oligomeric lactic acid content is 20 to 80 wt % and mucoadhesive agent content is from 10 to 65 wt %.EFFECT: improved properties.17 cl, 11 ex, 25 tbl, 9 dwg

New group of peptides for treatment of female sexual dysfunction // 2626002
FIELD: pharmacology.SUBSTANCE: peptides of general formula (I) are proposed: A-Thr-Lys-Hyp-B-C-D-X, where A is 0, Met, Met(O), Thr, Ala, His, Phe, Lys, Gly; B is 0, Gly, Asp, Trp, Gln, Asn, Tyr, Hyp, Arg; C is 0, Arg, Phe, Tyr, Gly, His, Hyp, Lys; D is 0, Val, Gly, Tyr, Trp, Phe, His; X is OH, OCH3, NH2; where 0 is the absence of amino acid residue, provided that if A≠0, then B, and/or C, and/or D≠0, if B≠0, then C and/or D≠0, excluding tetrapeptides, as well as peptides Phe-Thr-Lys-Hyp-Gly, Thr-Lys-Hyp-Hyp-Arg, Thr-Lys-Hyp-Arg-Gly. Pharmaceutical compositions containing these peptides and their application for treatment of women with a marked decrease in libido or with a complete lack of libido, with orgasmic dysfunction, sexual dysfunction not caused by organic disorders or diseases, HSDD, FSAD or FSIAD are also proposed.EFFECT: stimulated sexual properties and increased stability during storage.13 cl, 6 dwg, 4 tbl, 3 ex
Preparation method of the complex gel for mastitis treatment and prevention in cows and complex gel on its basis // 2624868
FIELD: veterinary medicine.SUBSTANCE: complex gel contains antimicrobial and anti-inflammatory drugs. As the antimicrobial drugs it contains metronidazole, chlorhexidine bigluconate 0.05%, tea fungus culture biomass. As the anti-inflammatory drugs it contains the plant components extracts: mother coltsfoot, chamomile pharmacy, birch buds, celandine, nettle, horseradish and chlorophytum, wherein the propylene glycol is used in the ratio of 1:5 as the extracting agent, additionally include the acrylic acid and triethanolamine in the following ratio, g/l: chlorhexidine digluconate 0.05% 9-13, metronidazole 3.5-5.0, acrylic acid 2.5-3.5, triethanolamine 1.0-1.5, mother coltsfoot extract 1.0-1.5, chlorophytum extract 1.0-1.5, chamomile pharmacy 1.0-1.5, birch buds extract 1.0-1.5, celandine extract 1.0-1.5, nettle extract 1.0-1.5, horseradish extract 1.0-1.5, tea fungus culture biomass - the rest. The claimed method of the complex gel preparation for the treatment and prevention of mastitis in cows concludes in mixing of antimicrobial and anti-inflammatory drugs, homogenization. The plant components are pre-dried, then in the amount of 1-1.5 g each it is homogenized and poured with the extractant. Propylene glycol is used as the extractant in the ratio of 1:5. It is additionally infused for 14-15 days and filtered. Prepare the tea fungus culture biomass, then infused for 10-12 days, then homogenize with the zoogloea of the tea fungus, dilute it with the infusion of tea fungus in the ratio of 1.6:1, respectively, until the homogeneous gel mass is obtained. Digest for 10-12 minutes, with further step by step addition of all components into the mixer, homogenization until the homogeneous gel mass is obtained and packed into the sterile syringes.EFFECT: claimed group of inventions application is highly effective for the mastitis treatment and prevention in cows.2 cl, 5 tbl, 9 ex

Pharmaceutical composition containing tetrahydropholic acid // 2624236
FIELD: pharmacology.SUBSTANCE: oral dosage form comprises progestogen, estrogen, 5-methyl-(6S)-tetrahydrofolic acid or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient or carrier, and comprises granulating of progestogen and estrogen and at least one pharmaceutically acceptable excipient in the fluidized bed, mixing of 5-methyl-(6S)-tetrahydrofolic acid or the pharmaceutically acceptable salt thereof with granules, and further granulation by maintaining the fluidized bed and formation of a solid oral dosage form from granules.EFFECT: compositions of the invention provide good stability of tetrahydrofolic acid during storage and at the same time provide a rapid release of estrogen and progestogen present in the composition.14 cl, 3 dwg, 5 tbl, 6 ex
Production method for ulipristal acetate and its intermediates // 2624007
FIELD: biotechnology.SUBSTANCE: invention relates to a method of producing ulipristal acetate which includes the following stages: where R is a hydroxyl protective group isolated from -CH(CH3)-OR1, where R1 is isolated from C1-C10 of alkyl and the dashed lines in formula V represent the double bonds in 5(10), 9(11) or 4(5), 9(10). The method also comprises of the following stages: a) use of 3.3-(ethylene dioxyl)-19-norpregn-5(10), 9(11)-diene-3.17-dione by formula II as the starting material and the use of spirits as the reaction solvent with cyan reagent to prepare the compound 3.3-(ethylene dioxy)-17β-cyano-7α-hydroxyl-19-norpregn-5(10), 9(11)-diene by formula III in a faintly acid medium at a temperature from -10°C to the room temperature; b) the production of the compound by formula IV via the reaction of the compound by formula III and hydroxyl protective group of the reagent in an acid medium in a solvent; c) interaction of the compound by formula IV with a methylating reagent and hydrolysis of compound by formula IV in an acid medium after a methylating reaction to obtain 5(10), 9(11)-diene-3.20-dione or 4(5), 9(10)-dienen-3.20-dione by formula V, or their mixture; d) interaction of the compound by formula V with ethylene glycol by the catalysis of p- toluenesulfonic acid and trimethyl orthoformate or triethyle orthoformate at the room temperature in dichloromethane with the yield of the compound 3.3-(ethylene-dioxy)-17α-hydroxy-19-norpregn-5(10), 9(11)-diene by formula VI; e) epoxidation of the compound in formula VI by hydrogen peroxide with the yield of the compound 3,3,20,20-bis (ethylene dioxyl)-17α-hydroxyl-5,10-epoxy-19-norpregn-9(11)-en by formula VII; f) additional reaction between the compound by formula VII and 4-(N, N-dimethyl amidogen) phenyl magnesium bromide of the Grignard reagent with the yield of the compound 3,3,20,20-bis(ethylene dioxy)-5α-17α-dihydroxy-11β--[4-(N,N-dimethylamino)-phenyl-]-19-norpregn-9(11)-en by formula VIII; g) the hydrolys of the compound by formula VIII in acid conditions with the production of 17α-hydroxy-11β-[4(N,N-dimethylamino)-phenyl-]-19-norpregn-9(11)-diene-3,20-dione by formula IX and h) the acetylation of the compound by formula IX with acetic acid, perchloric acid, acetic anhydride at a temperature of 0-10°C by dichloromethane with the production of the ulipristal acetate compound by formula I. The invention also relates to the compound by formula IV, to the method of production of the compound by formula IV, to the method of production of the compound by formula V.EFFECT: new method proposed for producing ulipristal acetate with a high yield and high purity of the final product, applicable in the industrial production.8 cl, 22 ex

Pharmaceutical delivery systems for hydrophobic medicinal products and compositions containing them // 2623206
FIELD: pharmacology.SUBSTANCE: pharmaceutical composition is claimed, containing a solubilized testosterone ester selected from testosterone enanthate, undecanoate, cypionate and palmitate.EFFECT: improved properties.14 cl, 15 dwg, 4 tbl
ethod for erectile dysfunction treatment // 2622757
FIELD: medicine.SUBSTANCE: fat tissue is taken from a patient under local anesthesia or intravenous anesthesia by liposuction in a volume of up to 250 ml. The fat tissue is processed on the Celution 800/CRS hardware complex for 1.5 hours and 4.0 ml of stromal-vascular fraction (SVF) is obtained. At that, the SWF contains 50 million or more cells. The SWF is then intracavernously administered to the patient at 6 points along the lateral surface of the penis bilaterally. 1.0 ml are administered proximally, 0.5 ml - medially and distally, total 2.0 ml per cavernous body. Then, a tightening garrot is put on the penis base for 15 minutes.EFFECT: increased effectiveness of treatment due to the absence of complications and side effects in patients with erectile dysfunction.2 ex

Application of liposomal dihydroquercetin emulsion "flamena" for treatment of chronic endometritis with autoimmune disorders in case of infertility // 2622024
FIELD: medicine.SUBSTANCE: effective treatment method represents a complex therapy that includes enzyme therapy, physical therapy, hormone therapy, as well as application of liposomal dihydroquercetin emulsion "Flamena".EFFECT: application of the method allows to achieve pregnancy for more than 90 percent of patients.3 cl, 3 dwg, 3 tbl, 3 ex
ethod of treatment of mastitis in lactating cows // 2622017
FIELD: veterinary medicine.SUBSTANCE: method comprises intracisternal injecting of the drug at a dose of 10.0 ml to the affected udder part with 12-hourly intervals 2-4 times. Injectable preparation contains succinic acid, ph-2 ASD, iodine and potassium iodide, the polyvinyl alcohol and procaine at the following component ratio, wt %: Succinic acid 1.0, ASD ph-2 2.0, 0.1 iodine, potassium iodide 0.5, procaine 0.5 polyvinyl alcohol 1.0, purified water is the rest.EFFECT: invention is highly effective for the treatment of mastitis in lactating cows.2 tbl, 3 ex
ethod for treatment of patients with sclerotic vulvar lichen // 2620683
FIELD: medicine.SUBSTANCE: method involves application of a complex therapy with the diagnosed sclerotic lichen, using autologous cellular regeneration by autoplasma enriched with platelets in combination with an antiviral drug and low-intensity laser light (LILI).EFFECT: use of the invention allows to reduce itching and dystrophic processes in the vulva area, accompanied by inflammatory manifestations in the dermis, fragmentation and disintegration of the elastic and nerve fibers, microcirculatory disturbances that characterize the sclerotic lichen, with formation of remission and prevention of disease progression into oncopathology.1 tbl
"viferon" application for pregnant women with hpv infection to prevent placenta infection and placental insufficiency // 2620547
FIELD: medicine.SUBSTANCE: invention can be used for prevention of placental insufficiency and placental infection for pregnant women with HPV infection. Viferon drug is applied by administering rectal suppositories in combination with intravaginal introduction of Viferon in the form of gel.EFFECT: use of the invention allows prevention of placental insufficiency and placental infection for pregnant women with PVI.4 dwg, 1 tbl
ethod of treatment of subclinical mastitis in lactating cows // 2619862
FIELD: veterinary medicine.SUBSTANCE: method involves a joint application of the Aminoseleton tissue specimen on days 1, 3 and 5 of the treatment course, which is administered subcutaneously in the upper third of the neck at a growing dose of 40-45-50 ml. The immunomodulator is administered in a dose of 10 ml intramuscularly on days 2, 4 and 6 of treatment. Bovine recombinant interferons α and γ are used as an immunomodulator.EFFECT: method is highly effective for the treatment of subclinical mastitis in lactating cows.3 tbl, 1 ex

Agent for pathozoospermia prevention and treatment // 2619330
FIELD: medicine.SUBSTANCE: dibornol application to male rats of reproductive age is proposed as a means of pathozoospermia prevention and correcting therapy. Dibornol is applied at a dose of 50 mg/kg of body weight 5 days before and 5 days after pathozoospermia induction by etoposide cytostatic.EFFECT: reduction of pathological forms of sperm, unlike mexidol antioxidant, dibornol restored the testes antioxidant activity , which may be associated with greater dibornol tropism to testicular tissue.6 dwg

Crystalline solvates of hydrochloride 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one // 2619129
FIELD: chemistry.SUBSTANCE: invention relates to organic chemistry, in particular to crystalline dihydrate 6-(piperidin-4-yloxy)-2H-isoquinolin-1-one of formula and a solid pharmaceutical composition thereof.EFFECT: obtained crystalline hydrochloride dihydrate, having better stability and hygroscopicity, which is preferable in obtaining the medicinal product based on it.16 cl, 14 dwg, 1 tbl

ethod and improved pharmaceutical composition for acceleration of pde-5 inhibitor transdermal delivery // 2618462
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to medicine and is a transdermal pharmaceutical composition in the form of gel or patch that contains vardenafil, enhancer selected from the group consisting of sodium lauroamphoacetate, quaternium-60, izostearamidopropil morpholine lactate and combinations thereof, and a pharmaceutically acceptable excipient. The enhancer accelerates the kinetics of transdermal absorption of vardenafil. Vardenafil and enhancer are present in the composition in a ratio from 20:1 to 2:1 by weight. The invention also relates to the method of acceleration of the transdermal delivery of vardenafil.EFFECT: invention provides transdermal delivery acceleration due to the vardenafil enhancer.8 cl, 2 ex, 2 dwg

Non-anticoagulant glycosaminoglycans with repeating disaccharide units, and their medical application // 2617764
FIELD: pharmacy.SUBSTANCE: invention refers to chemically modified glycosaminoglycan, which is heparin or heparan sulfate with anti-factor IIa activity less than 10 IU/mg, anti-factor Xa activity less than 10 IU/mg and average molecular weight from 4.6 to 6.9 kDa.EFFECT: invention also refers to a method for production of modified glycosaminoglycan and its medical application.45 cl, 3 dwg, 4 tbl
eans for farm animals postpartum endometritis treatment and prevention // 2617538
FIELD: veterinary medicine.SUBSTANCE: means comprises sodium bicarbonate, citric acid, sodium sulfate, calcium stearate, potato starch, ceftriaxone, carbacholine and aloe extract in the following ratio, wt %: ceftriaxone - 1.0; carbacholine - 0.05; aloe extract - 8.0; sodium bicarbonate - 38,95; citric acid - 32.0; sodium sulfate - 2.0; calcium stearate - 2.0; potato starch - 16.0.EFFECT: means enhances therapeutic efficacy, combines antibacterial, anti-inflammatory, contractive and restoring action.2 tbl, 3 ex
ethod of preparing pregnant women for labour induction with premature rupture of membranes in the absence of biological childbirth readiness at full-term period // 2617536
FIELD: medicine.SUBSTANCE: mifepristone at a dose of 200 mg is injected immediately after premature rupture of membranes to prepare pregnant women for labour induction with premature rupture of membranes in the absence of biological childbirth readiness at full-term period and after 6 hours the labour induction is started in the absence of labour activity.EFFECT: method enables to reduce lack of labour induction effect rate, reduce the frequency of labour activity abnormalities, fetal hypoxia, reduce the frequency of operative delivery, shorten the duration of latency period, improve perinatal indicators due to increase in the possibility of independent entry into labour within 6 hours after the premature rupture of membranes.2 tbl, 2 ex
ethod for regulation of sexual behavior and contraception of female mammals // 2617518
FIELD: veterinary medicine.SUBSTANCE: pharmaceutical composition is claimed as one intended for transdermal administration having a pH value in the range of 4.0 to 6.0 and the following quantitative and qualitative composition, (wt %): Gestagen 0.5÷2, Melatonin 10÷20, α-adrenergic blocker, αtropic to the posterior nuclei of the hypothalamus 1÷2, N-methyl-N-(1,2R,3R,4R,5S-pentahydroxyhexyl)-octadecanamide 0,5, D-panthenol 0,5, polyoxyethylated α-tocopherol 10, polyoxyethylated lanolin 1,3-(octadecyloxy)-1,2-propanediol 0,1, stearic acid 1,1, N,N-diethyltoluamide 15, 1,2-isopropylidene glycerol 20, 1,2,3- triacetoxypropane up to 100. A method for regulating sexual behavior and contraception of female animals is also claimed. It involveds administering the claimed pharmaceutical composition once in any sexual cycle period.EFFECT: use of the claimed group of inventions allows to effectively and safely regulate and conduct contraception of female animals.4 cl, 11 tbl, 39 ex
Pharmaceutical compositions comprising aromatase inhibitor // 2617510
FIELD: medicine, pharmacy.SUBSTANCE: this invention refers to low-dose pharmaceutical compositions comprising an aromatase inhibitor 4.4-'[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitril as an active ingredient in a suitable carrier. Furthermore, this invention refers to the process for their preparation and application as medicaments.EFFECT: invention expands the range of low-dose pharmaceutical compositions comprising the aromatase inhibitor.11 cl, 4 ex, 4 tbl
ethod of induction of superovulation in cows-donors embryones with prolongation of activity of hypophysical gonadotropins // 2617042
FIELD: veterinary medicine.SUBSTANCE: method comprises a single administration of donor cows in the luteal phase of the sexual cycle of the drug, containing pituitary gonadotropins Follicle stimulating hormone (FSH) and luteinizing hormone (LH), combined with prolongatory. After 48 hours, prostaglandin F2α is injected. Additionally, 0.25-1% novocaine solution in an amount of 3-15 ml is injected. This novocaine solution is injected simultaneously in combination with a preparation containing hypophyseal gonadotropins FSH and LH is combined with prolongatory, wherein prolongator is used as a biodegradable polymer is polyethylene glycol (PEG) with a mass of 6,000 to 70,000 Da in an amount of 0.5-7 g. The preparation, containing hypophyseal gonadotropins FSH and LH, is injeted in a total dose recommended by instructions of this drug to induce superovulation.EFFECT: method allows to increase the number of quality embryos obtained from donor cows as a result of induction of superovulation.1 tbl, 3 ex

Paroxetine derivative // 2616610
FIELD: chemistry.SUBSTANCE: invention relates to a new compound represented by the formula (1) wherein R1 represents a hydrogen atom, or its pharmacologically acceptable salt which has improved inhibitory effect towards CYP, as well invention relates to a pharmaceutical composition based on this compound having the action of the selective inhibitor of serotonin reuptake , an antidepressant, and an agent for the treatment or prevention of premature ejaculation.EFFECT: document describes a paroxetine derivative.18 cl, 1 dwg, 4 tbl, 1 ex
Composition for imporvement of human reproduction // 2616521
FIELD: pharmacology.SUBSTANCE: invention is a composition for women, comprising of L-arginine, magnesium citrate, ascorbic acid, Vitex agnus-castus extract containing aucubin, zinc citrate, tocopherol acetate, pyridoxine hydrochloride, riboflavin, folic acid, potassium iodate, sodium selenite and auxiliaries, wherein the components of the composition are in a certain ratio in milligrams per weight of 5000 mg sachet.EFFECT: improvement of the functional state of organs in the female reproductive system.4 tbl, 1 ex
ethod of correction of functional activity of ovaries when their hypofunction in cows // 2616256
FIELD: agriculture.SUBSTANCE: invention relates to the field of veterinary medicine and is intended for correction of functional activity of the ovaries when their hypofunction in cows. The method comprises treatment of animals with a preparation of natural sex pheromones of a bull, which is sprayed onto the nasoscope of animals at a dose of 0.5 ml/head twice a day in the morning and evening for 6 days, and 4 ml of 2.5% solution of progesterone is injected on the 1, 2 and 4 day intramuscularly as a single dose and on the 6 day 2 ml phertadine is administered in combination with 1000 IU follimag.EFFECT: claimed method is highly effective for the correction of functional activity of ovaries when their hypofunction in cows.2 tbl, 1 ex